Evidence based guideline for the management of high blood pressure in adults report from jnc 8
Download
1 / 21

EVIDENCE-BASED GUIDELINE FOR THE MANAGEMENT OF HIGH BLOOD PRESSURE IN ADULTS. REPORT FROM JNC 8 - PowerPoint PPT Presentation


  • 115 Views
  • Uploaded on

EVIDENCE-BASED GUIDELINE FOR THE MANAGEMENT OF HIGH BLOOD PRESSURE IN ADULTS. REPORT FROM JNC 8. DR. IDOWU AKOLADE EDM DIVISION LUTH. Hypertension remains one of the most important preventable contributor to disease and death.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' EVIDENCE-BASED GUIDELINE FOR THE MANAGEMENT OF HIGH BLOOD PRESSURE IN ADULTS. REPORT FROM JNC 8' - topper


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Evidence based guideline for the management of high blood pressure in adults report from jnc 8

EVIDENCE-BASED GUIDELINE FOR THE MANAGEMENT OF HIGH BLOOD PRESSURE IN ADULTS.REPORT FROM JNC 8

DR. IDOWU AKOLADEEDM DIVISIONLUTH


  • Hypertension remains one of the most important preventable contributor to disease and death.

  • It is the most common condition seen in primary care and leads to MI, RF, and death if not detected early and treated appropriately.

  • Patients want to be assured that BP treatment will reduce their disease burden while Clinicians wants guidance on HTN management using the best scientific evidence.

  • The report of JNC8 is long overdue, expected date mid 2011.


The panel members appointed to the 8 contributor to disease and death.th joint national committee (JNC8) used rigorous evidence based methods, developing evidence statements and recommendations for BP treatment based on a systematic review of literature to meet user needs.


Questions guiding evidence review
QUESTIONS GUIDING EVIDENCE REVIEW contributor to disease and death.

  • In adult with HTN, does initiating antihypertensive pharmacological therapy at specific BP thresholds improve health outcomes?

  • In adults with hypertension, does treatment with antihypertensive pharmacological therapy to a specified BP goal lead improvement in health outcomes?

  • In adult with hypertension, do various antihypertensive drugs or drug classes differ in comparative benefits and harms on specific health outcome?


What is known current recommendations for bp goals
WHAT IS KNOWN-CURRENT RECOMMENDATIONS FOR BP GOALS contributor to disease and death.

  • JNC7 <140/90 in general population, in diabetics or CKD <130/80.

  • AHA/ACC 2007, <130/80 in high risk population- CVD,CKD and DM.

  • ADA- DM<130/80

  • WHO/ISH-<140/90 in general population. In DM, CVD or CKD <130/80

  • NDOQI CKD<130/80

  • BHS<140/90 in general population, <130/80 DM,CVD and CKD.

  • ESH ‘’ at least’’ <130/80 in DM, CVD and CKD.


  • 9 recommendations were made based on evidence review. contributor to disease and death.

  • JNC8 recommendation for management of HTN

  • Recommendation 1-5- thresholds and goals for BP treatment

  • Recommendation 6,7,8 – selection of antihypertensive drugs.

  • Recommendation 9- starting and adding antihypertensive drugs.


R 1 contributor to disease and death.

  • In the general population aged ≥60, initiate pharmacologic treatment to lower BP at SBP of ≥150 or DBP ≥90 and treat to a goal of SBP <150 and DBP <90mmhg.

  • Corollary recommendation- if treatment results in lower achieved SBP e.g <140mmhg and treatment is not associated with adverse effect on health or QOL, treatment does not need to be adjusted.


R2 contributor to disease and death.

  • In general population <60yrs, initiate pharmacologic treatment to lower BP at DBP≥90mmhg and treat to a goal DBP <90mmhg(HOT trial).


R3 ish
R3-ISH contributor to disease and death.

  • In the general population <60yrs, initiate pharmacologic treatment to lower BP at SBP ≥140mmhg and treatment to a goal of SBP <140mmhg


R4 target
R4 TARGET contributor to disease and death.

  • In the general population aged ≥18yrs with CKD, initiate pharmacologic treatment to lower BP SBP ≥140mmhg a DBP ≥ 90 mmhg and treat to a goal of SBP<140mmhg or a goal DBP <90mmhg.

  • (AASK & MDRD trials)

  • Relevant clinical trial: AASK or MDRD. No benefit overall in CV or renal outcome.


R5 18 dm
R5 18+DM contributor to disease and death.

  • In the population aged ≥18yrs with diabetes, initiate pharmacologic treatment to lower BP at SBP ≥140mmhg or DBP ≥90mmhg and treat to a goal SDP <140mmhg and goal DBP<90mmhg.

  • (ACCORD-BP trial, UKPDS)

  • The accord BP trial evaluated the effect of targeting a SBP goal of 120mmhg compared to a goal of 140mmhg in patients with T2DM.

  • The result provide no conclusive evidence that the intensive BP control strategy reduces the rate of a composite of major CVD events in such patients.


R6 which one to start with
R6 : WHICH ONE TO START WITH contributor to disease and death.

  • In the general nonblack population, including those with diabetes, initial antihypertensive treatment should include a thiazide type diuretic, CCB, ACEI and ARB. Each of the four drug classes recommended by the panel yielded comparable effects on the overall mortality and cardiovascular, cerebrovascular and kidney outcome with one exception.

  • Initial treatment with thiazide was more effective than CCB or ACEI

  • ACEI was more effective than CCB in improving heart failure outcomes

  • Panel did not recommend B blocker for initial treatment of HTN because in one study , use of B blocker resulted in higher rate of cardiovascular death , MI or stroke.


R7 initial is thiazide
R7: INITIAL IS THIAZIDE contributor to disease and death.

  • In the general black population, including those with diabetes, initial antihypertensive treatment should include a thiazide type diuretic or CCB.( ALLHAT)

  • Thiazide more effective in improving cardiovascular, Heart failure and combined cardiovascular outcome compared to an ACEI in the black patient subgroup.


R8 ckd
R8 : CKD contributor to disease and death.

  • In the population aged ≥18yrs with CKD, initial ( or add-on) antihypertensive treatment should include an ACEI or ARB to improve kidney outcomes. This applies to all CKD patients with HTN regardless of the race or diabetes status.


R9 add one at a time
R9: ADD ONE AT A TIME contributor to disease and death.

  • Attain and maintain goal BP

  • If goal BP is not reached within one month of treatment, increase the dose of the initial drug or add a second drug from one of the classes in R6

  • Access BP and adjust the regimen until goal BP is reached.

  • If goal BP cannot be reached with 2 drugs , add and initiate a third drug form the list provided .

  • Do not use ACEI and ARB together.


  • If goal BP cannot be reached using only the drugs in Recommendation 6 because of a contraindication to the need to use more than 3 drugs to reach BP goal, antihypertensive drugs from other classes can be used.

  • Referral to a hypertension specialist may be indicated for patients in whom BP goal cannot be attained using the above strategies or for the management of complicated patients for whom additional clinical consultation is needed.


Comparison of current recommendations with jnc7 guidelines
COMPARISON OF CURRENT RECOMMENDATIONS WITH JNC7 GUIDELINES Recommendation 6 because of a contraindication to the need to use more than 3 drugs to reach BP goal, antihypertensive drugs from other classes can be used.


Conclusion
CONCLUSION Recommendation 6 because of a contraindication to the need to use more than 3 drugs to reach BP goal, antihypertensive drugs from other classes can be used.

  • Evidence based guideline has not redefined high BP and the panel believes that the 140/90mmhg definition of JNC7 remains reasonable.

  • For all patients with HTN, the potential benefits of healthy diet, weight control and regular exercise cannot be overemphasized.

  • These recommendations are not a substitute for clinical judgement and decision about care must carefully consider and incorporate the clinical characteristic circumstances of each individual patient.


References
References Recommendation 6 because of a contraindication to the need to use more than 3 drugs to reach BP goal, antihypertensive drugs from other classes can be used.

  • ICSI Hypertension evidence 2010 version.

  • Treatment blood pressure targets for HTN : Cochicine review 2009.

  • ACCORD- BP study march 14, 2010, effect of intensive BP control in T2DM

  • INVEST diabetes study group : tight blood pressure control and cardiovascular outcome among hypertensive patients with diabetes and CAD, JAMA vol 304,1, 61-67.

  • Hypertension in the very elderly trial ( HYVET) 2010. N Engl J Med 2008: 358 (18): 1887-98.

  • Staessen JA, Fagard R, Thijs L, et al; The Systolic Hypertension in Europe (Syst-Eur) Trial


References1
References Recommendation 6 because of a contraindication to the need to use more than 3 drugs to reach BP goal, antihypertensive drugs from other classes can be used.

  • 7. Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-1898.

  • 8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in

  • older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the

  • Elderly Program (SHEP). JAMA. 1991;265(24):3255-3264.

  • 9. Institute of Medicine. Clinical Practice Guidelines We Can Trust.Washington, DC: National Academies Press; 2011. http://www.iom.edu/Reports/2011 /Clinical-Practice-Guidelines-We-Can-Trust.aspx. Accessed November 4, 2013.

  • 10. Hsu CC, Sandford BA. The Delphi technique: making sense of consensus. Pract Assess Res Eval.

  • 2007;12(10). http://pareonline.net/pdf/v12n10.pdf. Accessed October 28, 2013.

  • 11. Institute of Medicine. Finding WhatWorks in Health Care: Standards for Systematic Reviews.


ad